Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $50 | $40 | $29 | $30 |
| % Growth | 25.3% | 38.5% | -3.9% | – |
| Cost of Goods Sold | $6 | $5 | $4 | $4 |
| Gross Profit | $43 | $34 | $25 | $26 |
| % Margin | 87.5% | 87.2% | 86.9% | 87.1% |
| R&D Expenses | $7 | $9 | $9 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $52 | $85 | $94 | $77 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $59 | $94 | $104 | $85 |
| Operating Income | -$15 | -$60 | -$79 | -$59 |
| % Margin | -30.8% | -151.7% | -276.5% | -200.3% |
| Other Income/Exp. Net | -$15 | -$16 | -$15 | -$15 |
| Pre-Tax Income | -$30 | -$76 | -$94 | -$74 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$76 | -$94 | -$74 |
| % Margin | -60.5% | -191.9% | -330.7% | -251% |
| EPS | -0.41 | -1.05 | -1.31 | -1.05 |
| % Growth | 61% | 19.8% | -24.8% | – |
| EPS Diluted | -0.41 | -1.05 | -1.31 | -1.05 |
| Weighted Avg Shares Out | 73 | 72 | 72 | 71 |
| Weighted Avg Shares Out Dil | 73 | 72 | 72 | 71 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $3 | $4 |
| Interest Expense | $16 | $18 | $18 | $19 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$58 | -$76 | -$56 |
| % Margin | -27.7% | -147.1% | -266.7% | -187.7% |